Patents for A61P 35 - Antineoplastic agents (221,099)
07/2007
07/11/2007CN1325115C Methods for CTL and T helper cell in therapeutic vaccination
07/11/2007CN1325108C Lesser galangal extract and its use
07/11/2007CN1325106C Chinese medicinal preparation for treating malignant tumor and production thereof
07/11/2007CN1325070C Chinese traditional medicine Tripterygium wilfordii and improving technique for attenuation and synergy of its extract
07/11/2007CN1325059C Application of ferriferrous oxide particle in preparation of tumour heating treatment auxiliary drug
07/11/2007CN1325049C Composition containing epigallocatechin gallate
07/10/2007USRE39723 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
07/10/2007US7241900 Synthesis of indole thiazole compounds as ligands for the Ah receptor
07/10/2007US7241894 Antitumor agents
07/10/2007US7241892 Hemisynthetic method and new compounds
07/10/2007US7241890 Heat shock protein 90 inhibitors; breast cancer, melanomas; inflammation, infectious diseases, autoimmune disorders, ischemia
07/10/2007US7241882 Polyamide nucleic acid derivatives, and agents, and processes for preparing them
07/10/2007US7241860 Transcription factor polypeptide that regulates Chondromodulin-I expression
07/10/2007US7241789 Substituted indoles and their use as integrin antagonists
07/10/2007US7241782 Modifications are prepared by subjecting an alkaline solution of torasemide to a rapid acidification with inorganic or organic acids at 0 to 35 degrees C.
07/10/2007US7241781 Thiazolyl inhibitors of Tec family tyrosine kinases
07/10/2007US7241777 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
07/10/2007US7241774 Amines such as 6,7-bis-hydroxy-1-biphenyl-4-ylmethyl-1,2,3,4-tetrahydro-isoquinoline, used as preferential anticarcinogenic agents
07/10/2007US7241769 Pyrimidines as PLK inhibitors
07/10/2007US7241763 3-furanyl analogs of toxoflavine as kinase inhibitors
07/10/2007US7241755 E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents
07/10/2007US7241754 2-Desmethyl ansamycin compounds
07/10/2007US7241747 For therapy and prophylaxis of diseases where bone formation is desired, such as osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus; also exhibit pronounced activity in arresting the proliferation of undifferentiated cells
07/10/2007US7241745 Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives
07/10/2007US7241742 Nucleotide sequences coding polypeptides for use in the treatment of cell proliferative disorders
07/10/2007US7241738 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
07/10/2007US7241733 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
07/10/2007US7241619 Identification of genes encoding enzymes (Thraustochytrium aureum Delta 5-desaturase, Saprolegnia diclina Delta 5-desaturase, Saprolegnia diclina Delta 6-desaturase)involved in synthesis of polyunsaturated fatty acids
07/10/2007US7241618 A polynucleotide comprising a RNA polymerase promoter, able encoding a siRNA; treating cancer and genetic disorders; genetic engineering, inhibit gene expression of a target gene
07/10/2007US7241591 Adenovirus comprising a gene coding for glutathione peroxidase
07/10/2007US7241576 Applications of a novel cytokine, named THANK, for TNF homologue that activates apoptosis, NF- kappa B and c-jun N-terminal kinase. Such applications include using THANK inhibitors to inhibit the activation of NF-kappa B and to
07/10/2007CA2466340C Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
07/10/2007CA2421910C Xanthine phosphodiesterase v inhibitors
07/10/2007CA2396814C Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical compositions containing them
07/10/2007CA2380072C Nicotine in therapeutic angiogenesis and vasculogenesis
07/10/2007CA2378628C New indenoindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them
07/10/2007CA2367092C Method for treating and/or preventing retinal diseases with sustained release corticosteroids
07/10/2007CA2238313C Thermolabile uracil-dna-glycosylase, process for its production and use for removing uracil from dna
07/10/2007CA2199401C Pyrimido[5,4-d]pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
07/10/2007CA2190807C Acetylsalicylic acid and tocopherol stable pharmaceutical composition
07/10/2007CA2124769C Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
07/10/2007CA2098849C Control of gene expression by ionizing radiation
07/10/2007CA2087818C Oligonucleotide analogs, their preparation and use
07/09/2007CA2635370A1 Modulators of hypoxia inducible factor-1 and related uses
07/05/2007WO2007076474A1 Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
07/05/2007WO2007076085A2 Fused pyrimidones and thiopyrimidones, and uses thereof
07/05/2007WO2007075870A2 Processes for taxane derivatives and intermediates useful therein
07/05/2007WO2007075825A2 Lipophilic anticancer drug compounds
07/05/2007WO2007075808A2 Methods for preventing and/or treating a cell proliferative disorder
07/05/2007WO2007075605A2 Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production
07/05/2007WO2007075554A2 Combination of igfr inhibitor and anti-cancer agent
07/05/2007WO2007075525A2 Combination of an iap-inhibitor and a taxane7
07/05/2007WO2007075492A1 Lipophilic anticancer drug compounds
07/05/2007WO2007075465A1 Dimers and adducts of 6-[(substituted) phenyl] triazolopyrimidines useful as anticancer agents
07/05/2007WO2007075387A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
07/05/2007WO2007075119A1 Pharmaceutical composition for photodynamic therapy and a method for treating oncological diseases by using said composition
07/05/2007WO2007075077A1 Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
07/05/2007WO2007074916A1 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity
07/05/2007WO2007074909A1 Controlled release solid preparation
07/05/2007WO2007074859A1 Anti-c-mannosylated peptide antibody and use thereof
07/05/2007WO2007074788A1 Anti-tumor agent and immunostimulating agent
07/05/2007WO2007074707A1 THERAPEUTIC AGENT FOR NEUROBLASTOMA TARGETING ARID3b
07/05/2007WO2007074641A1 Pharmaceutical preparation of aqueous solution containing platinum complex
07/05/2007WO2007074604A1 Nanoparticle containing water-soluble non-peptidic low molecular weight substance
07/05/2007WO2007074347A1 21-deoxymacbecin analogues useful as antitumor agents
07/05/2007WO2007074176A1 Novel pyrrole derivatives with histone deacetylase inhibitor activity
07/05/2007WO2007073785A1 Therapeutic use of an extract from the leaves of nerium oleander
07/05/2007WO2007073651A1 4,5-seco abieta diterpene quinones, preparation and use thereof
07/05/2007WO2007073646A1 The application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation, chemotherapy sensitization
07/05/2007WO2007073583A1 A method of treatment and agents useful for same
07/05/2007WO2007056596A3 Phosphoramidate derivatives of fau
07/05/2007WO2007010012A3 Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
07/05/2007WO2007008566A3 Inorganic shell-based radionuclide nanoparticles bound to biomolecules
07/05/2007WO2006135949A3 Tumour treatment with gliotoxin derivatives
07/05/2007WO2006067466A3 Pyrazines and pyridines and derivatives thereof as therapeutic compounds
07/05/2007US20070157326 Ee3-protein family and corresponding dna sequence
07/05/2007US20070155841 Preventive agent for carcinogenesis of liver cancer containing quinone-based compound as active ingredient
07/05/2007US20070155833 Oxaliplatin formulations
07/05/2007US20070155816 CDK(Cyclin-dependent kinase) inhibitor; cancer, apoptosis; 5-NH-trimethyl-indirubin-3-oxime
07/05/2007US20070155814 Immunomodulatory compositions
07/05/2007US20070155808 G Protein-Coupled Receptors (GPR40); insulin secretagogue; diabetes; 3-[4-[[4-[[(2-Phenylethyl)(4-phenyl-1,3-thiazol-2-yl)amino]methyl]benzyl]oxy]phenyl]propanoic acid
07/05/2007US20070155796 Crystals of benzimidazole compounds
07/05/2007US20070155756 Treatment of chemokine mediated diseases
07/05/2007US20070155745 e.g. 2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; blood coagulation factor and trypsin-like serine protease inhibitor; anticoagulant, antiinflammatory agent; atherosclerotic plaque, myocardial infarction and unstable angina
07/05/2007US20070155734 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
07/05/2007US20070155732 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
07/05/2007US20070155724 Methods of Treating Cytokine Mediated Diseases
07/05/2007US20070155713 Nitrogen-containing heterocyclic compounds and use thereof
07/05/2007US20070155703 Pharmaceutically active compounds and methods of use thereof
07/05/2007US20070155689 Methods of regulating growth and death of cancer cells
07/05/2007US20070154995 Development of human monoclonal antibodies and uses thereof
07/05/2007US20070154933 Reagents and Methods for Identifying Gene Targets for Treating Cancer
07/05/2007US20070154912 87 Human Secreted Proteins
07/05/2007US20070154908 Connective Tissue Growth Factor-2
07/05/2007US20070154905 Modulators of the function of fas receptors and other proteins
07/05/2007US20070154902 Papilloma virus vaccine
07/05/2007US20070154566 Method for preparing therapeutic agent for cancer
07/05/2007US20070154486 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin
07/05/2007US20070154485 Anticancer agents using verotoxin variants
07/05/2007US20070154483 Treatment with anti-vegf antibodies